Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis

Rheumatology International

Volumn 32, Issue 11, 2012, Pages 3397-3403

  Xu, Shengqian ^a   Wang, Yu ^a   Lu, Jingqiu ^b   Xu, Jianhua ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Hefei Public Security Bureau   (China)

Author keywords

Osteoporosis; Osteoprotegerin; Receptor activator of nuclear factorkappa B ligand; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; AGED; ARTICLE; BONE DENSITY; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMUR NECK; FOREARM; GREATER TROCHANTER; HUMAN; JOINT SWELLING; LUMBAR SPINE; MALE; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROXIMAL FEMUR FIXATION DEVICE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BONE DENSITY; FEMALE; FEMUR; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPROTEGERIN; RANK LIGAND;

EID: 84872188518     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-2175-5     Document Type: Article

References (33)

1. Romas E, Gillespie MT, Martin TJ (2002) Involvement of receptor activator of NFjB ligand and tumor necrosis factor-A in bone destruction in rheumatoid arthritis. Bone 30:340-346 (PubMed: 11856640) (Pubitemid 34154863)
2. Abu-Amer Y, Abbas S, Hirayama T (2004) TNF receptor type I regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis. J Cell Biochem 93:980-989 (PubMed: 15389885) (Pubitemid 44264151)
3. Gravallese EM, Goldring SR (2000) Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 43:2143-2151 (PubMed: 11037873)
4. Hofbauer LC, Heufelder AE (2001) The role of osteoprotegerin and receptor activator of nuclear factor jB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum 44:253-259 (PubMed: 11229454) (Pubitemid 32207017)
5. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E et al (2000) Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 43:250-258 (PubMed: 10693863) (Pubitemid 30395732)
6. Saidenberg KN, Con'ado A, Lemeiter D (2004) TNF-A antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 35:1200-1207 (PubMed:15542046) (Pubitemid 39487367)
7. Khosla S (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology 142:5050-5055 (PubMed:11713196) (Pubitemid 33131929)
8. Page G, Miossec P (2005) RANK and RANKL expression as markers of dendritic cell -T cel1 interactions in paired samples of rheumatoid synovium and lymph nodes. Arthritis Rheum 52:2307-2312 (PubMed:16052586) (Pubitemid 41117414)
9. Kostenuik PJ, Shalhoub V (2001) Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 7:613-635 (PubMed:11375772) (Pubitemid 32427765)
10. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T et al (1998) Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247:610-615 (PubMed: 9647741) (Pubitemid 28418439)
11. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C et al (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323 (PubMed: 9950424)
12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324 (PubMed: 3358796) (Pubitemid 18091653)
13. Liu Z, Piao J, Pang L, Qing X, Nan S, Pan Z et al (2002) The diagnostic criteria for primary osteoporosis and the incidence of osteoporosis in China. J Bone Miner Metab 20:181-189 (Pub-Med: 12115062) (Pubitemid 41184331)
14. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M et al (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331-337 (PubMed: 11685647) (Pubitemid 33041725)
15. Gravallese EM (2002) Bone destruction in arthritis. Ann Rheum Dis 61(Suppl 2):ii84-ii86 (PubMed: 12379632) (Pubitemid 35221724)
16. Sinigaglia L, Varenna M, Girasole G, Bianchi G (2006) Epidemiology of osteoporosis in rheumatic diseases. Rheum Dis Clin North Am 32:631-658 (PubMed: 17288969)
17. Bekker PJ, Holloway D, Nakanishi A, Arrighi HM, Leese PT, Dunstan CR (2001) Osteoprotegerin (OPG) has potent and sustained antiresorptive activity in post menopausal women. J Bone Miner Res 16:348-360 (PubMed:11204435)
18. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R et al (1997) Osteoprotegerina: a noval secreted protein involved in the regulation of bone density. Cell 89:309-319 (PubMed: 9108485) (Pubitemid 27199902)
19. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176 (PubMed:9568710) (Pubitemid 28180851)
20. Wong BR, Josien R, Lee SY, Sauter B, Li HL, Steinman RM et al (1997) TRANCE (tumor necrosis factor [TNF]-related activationinduced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 86:2075-2080 (PubMed:9396779) (Pubitemid 28013694)
21. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S et al (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304-309 (PubMed: 10580503) (Pubitemid 129516268)
22. Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W et al (2002) High levels of Osteoprotegerin and soluble receptor activator of nuclear factor j B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor a treatment. Arthritis Rheum 46:1744-1753 (PubMed: 12124857) (Pubitemid 34774505)
23. Skoumal M, Kolarz G, Haberhauer G, Woloszczuk W, Hawa G, Klingler A (2005) Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Rheumatol Int 26:63-69 (PubMed: 15889303) (Pubitemid 41531517)
24. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E et al (2001) Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 44:1003-1012 (PubMed: 11352231) (Pubitemid 32433604)
25. Vanderborght A, Linsen L, Thewissen M, Geusens P, Raus J, Stinissen P (2004) Osteopmtegerin and receptor activator of nuclear factor-kappa B ligand mRNA expression in patients with rheumatoid arthritis and healthy controls. J Rheumatol 31:1483-1490 (PubMed: 15290725) (Pubitemid 39006627)
26. Haynes DR, Crotti TN, Capone M, Bain GI, Atkins GJ, Findlay DM (2001) Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford) 40:623-630 (PubMed: 11426018)
27. Nosaka K, Miyamoto T, Sakai T, Mitsuya H, Suda T, Matsuoka M (2002) Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor jB ligand on adult T-cell leukemia cells. Blood 99:634-640 (PubMed: 11781248) (Pubitemid 34533102)
28. Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK (2000) Bone mineral density and frequency of osteoporosis in female patient with rheumatoid arthritis: result from 394 patients in the Olso county rheumatoid arthritis register. Arthritis Rheum 43:522-530 (PubMed: 10728744) (Pubitemid 30394942)
29. Urbanek R, Tlustochowicz W, Patola J, Glodzik J (2000) Incidence of osteoporosis in patients with rheumatoid arthritis. Przegl Lek 57:103-107 (PubMed: 10907352)
30. Oelzner P, Franke S, Lehmann G, Eidner T, Muller A, Wolf G et al (2007) Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis relationship with bone mineral density, disease activity and bone turnover. Clin Rheumatol 26:2127-2135 (PubMed: 17541498) (Pubitemid 350120353)
31. Lodder MC, de Jong Z, Kostense PJ, Molenaar ET, Staal K, Voskuyl AE et al (2004) Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density. Ann Rheum Dis 63:1576-1580 (PubMed: 15547081) (Pubitemid 39573684)
32. Saidenberg-Kermanac'h N, Cohen-Solal M, Bessis N, De Vernejoul MC, Boissier MC (2004) Role for osteoprotegerin in rheumatoid inflammation. Joint Bone Spine 71:9-13 (PubMed: 14769514) (Pubitemid 38183280)
33. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, The Denosumab Rheumatoid arthritis Study Group et al (2008) Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelvemonth, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58:1299-1309 (PubMed: 18438830) (Pubitemid 351705919)